Roth Mkm initiated coverage on shares of Nuwellis (NASDAQ:NUWE – Free Report) in a research report sent to investors on Monday, Marketbeat Ratings reports. The firm issued a buy rating and a $17.00 price objective on the stock.
Nuwellis Stock Performance
NASDAQ NUWE opened at $2.76 on Monday. The firm has a 50-day simple moving average of $5.72 and a 200 day simple moving average of $11.24. Nuwellis has a twelve month low of $2.19 and a twelve month high of $92.75. The stock has a market cap of $1.79 million, a PE ratio of -0.01 and a beta of 0.44.
Nuwellis (NASDAQ:NUWE – Get Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($21.00) earnings per share (EPS) for the quarter. Nuwellis had a negative return on equity of 316.90% and a negative net margin of 202.97%. The business had revenue of $1.86 million during the quarter. Research analysts forecast that Nuwellis will post -7 earnings per share for the current fiscal year.
Nuwellis Company Profile
Nuwellis, Inc, a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics.
Further Reading
- Five stocks we like better than Nuwellis
- Most active stocks: Dollar volume vs share volume
- First Solar Stock: The Dawn of a New Rally in Share Prices
- How Can Investors Benefit From After-Hours Trading
- Mastercard Stock’s Q2 Financial Results Outshine Competitors
- Investing in large cap stocks: Diving into big caps
- Tobacco Giant’s Shares Fall on EPS Miss, Lackluster Pouch Gains
Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.
